Lenalidomide with targeted therapy and immunotherapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding lenalidomide (a drug that boosts the immune system) to your current targeted therapy and immunotherapy can help advanced liver cancer that has progressed after previous treatments. You would be eligible if your cancer has already been treated with at least two prior drug combinations and initially responded before growing back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Diagnosed with hepatocellular carcinoma (liver cancer) that cannot be surgically removed, is locally advanced, or has spread
- Previously received at least two lines of systemic therapy, including both targeted therapy and immunotherapy (checkpoint inhibitors)
- Your most recent treatment initially worked (shrunk the tumor or stopped growth for 4+ weeks) before the cancer progressed
- At least one measurable tumor on imaging scans
- Good overall health status (able to carry out normal activities with minimal assistance)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (sintilimab, an immunotherapy, and lenvatinib, a targeted therapy) followed by local treatments to try to cure advanced liver cancer that has spread to a few other parts of the body. The goal is to shrink the cancer enough that surgery or radiation can remove it completely.
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
This study tests two targeted therapy drugs, lenvatinib or regorafenib, for people with advanced liver cancer that got worse after first treatment with immunotherapy. It aims to see if these drugs can help when immunotherapy stops working.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This trial tests if adding rituximab to previous cancer treatments can help people with advanced hepatocellular carcinoma (a type of liver cancer) that has stopped responding or caused side effects. It aims to see if this combination is safe and effective.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.